TVTX

47.0002.69%
JI

Jula Inrig

Executive VP, Head of Research & Development and Chief Medical Officer

Dr. Jula Inrig, M.D., is Chief Medical Officer of Travere Therapeutics, Inc. from January 04, 2022 and is its Executive Vice President and Head of Research & Development since July 1, 2026. Dr. Inrig served as Global Head of the Renal Center of Excellence at IQVIA, where she helped lead the design and execution of clinical development programs that supported regulatory approvals in kidney disease and oversaw numerous global clinical trials, including pivotal studies in IgA nephropathy and FSGS. While at IQVIA, Dr. Inrig was instrumental in the design, execution and strategy of clinical trials leading to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals in autosomal dominant polycystic kidney disease (ADPKD) and diabetic kidney disease. Dr. Inrig served as an inaugural member of the board for the Kidney Health Initiative, a public-private partnership with the FDA founded with the goal of improving the development of therapies for patients with kidney disease. Dr. Inrig has also served in advisory roles for national societies and their guidelines including the American Society of Nephrology, the National Kidney Foundation and the American Heart Association. Dr. Inrig has more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement. Dr. Inrig joins the Company as it prepares for accelerated approval submissions of sparsentan for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) in 2022, as well as the continued advancement of its pegtibatinase program in classical homocystinuria (HCU). Dr. Inrig is board certified in Nephrology and Internal Medicine and has served on the faculty at the University of California, Irvine and as an adjunct in the Department of Medicine at the Duke University School of Medicine. Dr. Inrig received her M.D. from Loma Linda University and completed her Internal Medicine Residency, her Nephrology Fellowship and obtained a Master of Health Science at Duke University. Dr. Inrig holds a B.A. from California State University, Sacramento.

Positions